Kim Kelderman Power - 08 Sep 2025 Form 4 Insider Report for CONMED Corp (CNMD)

Reporting relationship: Director
Issuer ticker: CNMD
Reported as of: 08 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2025, 16:13:35 UTC
Prior SEC filing: 19 Aug 2025
Next SEC filing: 05 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas Fistek for Kim Kelderman by Power of Attorney

Key filing fact

Kim Kelderman Power filed Form 4 for CONMED Corp (CNMD) on 09 Sep 2025.

Key facts

This page summarizes Kim Kelderman Power's Form 4 filing for CONMED Corp (CNMD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Sep 2025, 16:13.

Change

Previous filing in this sequence was filed on 19 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001739054 Primary reporting owner

Kelderman Kim

Relationship: Director
Address: C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO
Signature: /s/ Thomas Fistek for Kim Kelderman by Power of Attorney
Signature date: 09 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNMD transaction Derivative

RSUs (Restricted Stock Units)

Award

Transaction value: $0
Shares: +500
Change %
Price: $0.000000
Shares after: 500
Date: 08 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500
Exercise price: $0.000000
Footnotes: F1, F2

CNMD transaction Derivative

Options To Purchase Common Stock

Award

Transaction value: $0
Shares: +6,227
Change %
Price: $0.000000
Shares after: 6,227
Date: 08 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,227
Exercise price: $53.83
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.

Footnote F2

The stock options were granted under the 2025 Long-Term Incentive Plan of CONMED Corporation (the "Company) and generally vest 100% 1 year from the grant date.